Ceftobiprole Medocaril under Phase III trials is expected to turn out to be the most effective treatment of Acute Bacterial Skin and Skin Structure Infections.
Los Angeles, USA, May 24, 2021 (GLOBE NEWSWIRE) -- Acute Bacterial Skin and Skin Structure Infections Pipeline Featuring Plethora of Emerging Drugs, Key Companies
Ceftobiprole Medocaril under Phase III trials is expected to turn out to be the most effective treatment of Acute Bacterial Skin and Skin Structure Infections.
DelveInsight’s ‘Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Pipeline Insights’ report offers a detailed picture of the ABSSSI emerging therapies expected to enter the Acute Bacterial Skin and Skin Structure Infections market along with detailed coverage of the pipeline therapies under development in pre-clinical as well as clinical stages of development, partnerships taking place in the domain, recent happenings in space and growth prospects across the Diabetes domain.
Acute Bacterial Skin and Skin Structure Infections Drug Pipeline report offer a comprehensive analysis of 15+ key players and 15+ key therapies.
ABSSSI pipeline comprises TNP-2092 (TenNor Therapeutics), TXA709 (Taxis Pharmaceuticals), Afabicin (Debiopharm Group), Ceftobiprole Medocaril (Basilea Pharmaceutica), Brilacidin (Innovation Pharmaceuticals), Cannabidiol (Botanix Pharmaceuticals), and several others expected to get launched in the next decade.
Out of all the emerging therapies, Ceftobiprole Medocaril the prodrug of the active moiety ceftobiprole, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria being investigated in Phase III clinical trial will turn out to be the most effective treatment of the treatment of Acute Bacterial Skin and Skin Structure Infections.
Afabicin (Debio 1450), is a new antibiotic being developed by Debiopharm benefiting from both oral and IV formulations. It is a highly potent, staphylococcus-selective antibiotic with a low propensity to the emergence of resistance. This first-in-class FabI inhibitor retains its activity on staphylococci strains resistant to antibiotics currently in clinical use including beta-lactams, vancomycin, daptomycin or linezolid. The therapeutic candidate is set to be evaluated in bone and joint infections caused by staphylococci. The drug has completed a large Phase II study for Acute Bacterial Skin and Skin Structure Infections treatment.
TXA709 targets ABSSSI caused by Staphylococcus aureus, including methicillin-resistant strains. The drug has received a Qualified Infectious Disease Product (QIDP) designation from the U.S. Food and Drug Administration. TXA709 is a prodrug, a biologically inactive compound that can be metabolized in the body to produce a drug, TXA707, a derivative of benzoic acid that disrupts the form and function of the bacterial protein FtsZ, which plays an essential role in bacterial cell division.
Acute Bacterial Skin and Skin Structure Infection is a bacterial infection of the skin and associated tissues. The FDA defines skin and skin structure infections as an acute bacterial skin and skin structure infection or ABSSSI if the infection is accompanied by redness, edema, and/or induration of a minimum surface area of 75 cm2, accompanied by lymph node enlargement or systemic symptoms such as fever ≥38°C (100.4°F).
Some of the most common bacterial pathogens that cause Acute Bacterial Skin and Skin Structure Infections are Streptococcus pyogenes and Staphylococcus aureus, including methicillin-resistant S.aureus. Less common causes include other Streptococcus species, Enterococcus faecalis, or Gram Negative bacteria.
The severity of Acute Bacterial Skin and Skin Structure Infections has led to an increasing emphasis on the identification of novel strategies to treat this disease.
The ABSSSI Pipeline report presents comprehensive insights into active ABSSSI pipeline assets segmented by Stage, ABSSSI Product Type, Route of Administration, Molecule Type, Target, and Indications of various drugs.
By Product Type
Mono
Combination
By Stage
Discovery
Pre-clinical
IND
Phase I
Phase II
Phase III
Pre-registration
By Molecule Type
Small Molecule
Gene Therapy
Stem Cell Therapy
By Route of Administration
Intravenous
Intramuscular
Oral
Subcutaneous
By Mechanism of Action
Cell wall inhibitors
Cell membrane permeability enhancers
Enoyl-ACP reductase inhibitors
DNA gyrase inhibitors
Bacterial FtsZ protein inhibitors
Cannabinoid receptor CB1 inverse agonists
By Targets
Protease
Multiple Kinase
By Stage and Route of Administration By Stage and Product Type
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
